Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab - 23/11/17
Abstract |
Background |
Rituximab is an effective therapy for pemphigus, although relapses are common.
Objective |
To identify biomarkers to predict relapse of pemphigus following rituximab treatment.
Methods |
In this retrospective cohort study, 62 patients with pemphigus treated with 99 rituximab cycles provided longitudinal clinical scoring and biomarker data, including levels of CD19+ B cells, CD4+ T cells, and desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) autoantibodies. An extended time-variant Kaplan-Meier estimator and extended Cox model were applied.
Results |
Relapse was rare before B-cell repopulation. Univariate analysis revealed low CD4 count (<400 cells/μL) to predict relapse (P < .001). A positive result of testing for Dsg1 (>20 IU) was predictive of relapse among patients with mucocutaneous disease (hazard ratio, 6.40; P = .019); a positive result of testing for Dsg3 (>20 IU) was predictive in patients with mucocutaneous and mucosal disease (hazard ratio, 32.92; P < .001). Multivariable analysis revealed that every CD4 value increase of 200 decreases the hazard ratio for relapse by 35% (P = .029). A positive result of testing for Dsg1 increases the risk for relapse by a factor of 12.32 in patients with mucocutaneous disease (P = .001); positive result of testing for Dsg3 increases risk for relapse by 28.38 in patients with mucosal and mucocutaneous disease (P = .006).
Limitations |
Limitations include the retrospective design and inconsistent follow-up.
Conclusion |
Relapse is associated with B-cell repopulation, low CD4+ T -cell count, and positive result of testing for Dsg1 and Dsg3.
Le texte complet de cet article est disponible en PDF.Key words : autoantibodies, autoimmune bullous diseases, immunology, pemphigus, pemphigus foliaceus, pemphigus vulgaris, prediction, relapse, rituximab
Abbreviations used : Dsg1, Dsg3, EKM, PDAI, RA, SD
Plan
| Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (award No. UL1TR000454). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 77 - N° 6
P. 1074-1082 - décembre 2017 Retour au numéro
Article précédent
- Use of oral antidepressants in patients with chronic pruritus: A systematic review
- Tessa A. Kouwenhoven, Peter C.M. van de Kerkhof, Marijke Kamsteeg
- Obesity and risk for incident rosacea in US women
- Suyun Li, Eunyoung Cho, Aaron M. Drucker, Abrar A. Qureshi, Wen-Qing Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?